These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Tamesis RR; Rodriguez A; Christen WG; Akova YA; Messmer E; Foster CS Ophthalmology; 1996 May; 103(5):768-75. PubMed ID: 8637685 [TBL] [Abstract][Full Text] [Related]
26. Ocular toxicity from systemically administered xenobiotics. Gokulgandhi MR; Vadlapudi AD; Mitra AK Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1277-91. PubMed ID: 22803583 [TBL] [Abstract][Full Text] [Related]
27. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Fu C; Gombos DS; Lee J; George GC; Hess K; Whyte A; Hong DS Oncotarget; 2017 Aug; 8(35):58709-58727. PubMed ID: 28938590 [TBL] [Abstract][Full Text] [Related]
28. The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. Rühle A; Huber PE; Saffrich R; Lopez Perez R; Nicolay NH Int J Cancer; 2018 Dec; 143(11):2628-2639. PubMed ID: 29931767 [TBL] [Abstract][Full Text] [Related]
29. Ocular side effects of oncological therapies: Review. Asencio-Durán M; Fernández-Gutiérrez E; Larrañaga-Cores M; Klein-Burgos C; Dabad-Moreno JV; Capote-Díez M Arch Soc Esp Oftalmol (Engl Ed); 2024 Mar; 99(3):109-132. PubMed ID: 37949110 [TBL] [Abstract][Full Text] [Related]
30. Current antiangiogenic agents in oncology and ophthalmology. Cernak M; Nogova L Neoplasma; 2016; 63(1):10-7. PubMed ID: 26780840 [TBL] [Abstract][Full Text] [Related]
31. Ocular findings in breast cancer patients using tamoxifen. Ugurlu S; Karagoz A; Altin Ekin M Cutan Ocul Toxicol; 2015 Mar; 34(1):16-20. PubMed ID: 24678744 [TBL] [Abstract][Full Text] [Related]
32. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
33. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
34. More than meets the eye: the ocular toxicities accessory to anticancer therapies. Fortes BH; Tailor PD; Dalvin LA Future Oncol; 2023 Jan; 19(3):189-191. PubMed ID: 36891943 [No Abstract] [Full Text] [Related]
35. Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial. D'Almeida Preto D; Baston MT; Geraige CC; Augusto SB; de Oliveira MA; Mamere AE; Pinto GDJ; Dias JM; De Marchi PRM; Paiva BSR; Paiva CE BMC Cancer; 2019 Apr; 19(1):382. PubMed ID: 31023257 [TBL] [Abstract][Full Text] [Related]
37. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Abramson DH; Dunkel IJ; Brodie SE; Kim JW; Gobin YP Ophthalmology; 2008 Aug; 115(8):1398-404, 1404.e1. PubMed ID: 18342944 [TBL] [Abstract][Full Text] [Related]
38. Ocular side effects of chemotherapy: nursing management. Cloutier AO Oncol Nurs Forum; 1992 Sep; 19(8):1251-9. PubMed ID: 1408967 [TBL] [Abstract][Full Text] [Related]
39. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661 [TBL] [Abstract][Full Text] [Related]
40. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Miserocchi E; Baltatzis S; Roque MR; Ahmed AR; Foster CS Ophthalmology; 2002 Jan; 109(1):111-8. PubMed ID: 11772589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]